NERV vs. TLPH, GLYC, TRAW, FLGC, VBIV, VINC, GLTO, AYTU, SLGL, and INDP
Should you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include Talphera (TLPH), GlycoMimetics (GLYC), Traws Pharma (TRAW), Flora Growth (FLGC), VBI Vaccines (VBIV), Vincerx Pharma (VINC), Galecto (GLTO), Aytu BioPharma (AYTU), Sol-Gel Technologies (SLGL), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical preparations" industry.
Minerva Neurosciences (NASDAQ:NERV) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.
Minerva Neurosciences received 343 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 60.56% of users gave Minerva Neurosciences an outperform vote.
Minerva Neurosciences presently has a consensus target price of $7.00, indicating a potential upside of 182.26%. Talphera has a consensus target price of $4.50, indicating a potential upside of 320.56%. Given Talphera's stronger consensus rating and higher probable upside, analysts clearly believe Talphera is more favorable than Minerva Neurosciences.
Minerva Neurosciences' return on equity of 0.00% beat Talphera's return on equity.
In the previous week, Talphera had 13 more articles in the media than Minerva Neurosciences. MarketBeat recorded 14 mentions for Talphera and 1 mentions for Minerva Neurosciences. Talphera's average media sentiment score of 0.50 beat Minerva Neurosciences' score of 0.00 indicating that Talphera is being referred to more favorably in the news media.
Talphera has higher revenue and earnings than Minerva Neurosciences. Talphera is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.
Minerva Neurosciences has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.
34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 6.4% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 3.0% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Talphera beats Minerva Neurosciences on 11 of the 16 factors compared between the two stocks.
Get Minerva Neurosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Minerva Neurosciences Competitors List
Related Companies and Tools
